

SAFETY Meeting Minutes

Biosafety Committee

12/19/2025 2:00 PM

Zoom

MEETING TIME RECORDS**Meeting start time:** 2:04 PM**Meeting end time:** 2:18 PM**VOTING MEMBER ATTENDANCE**

Name	Substituting For	Attendance
Mark Klang		Present
Andy Koff		Absent
Xiuyan Wang		Absent
Prasad Adusumilli		Present
Justin Laracy		Present
Lauren Wood		Absent
Paul Zel		Present
Philip Hauck		Absent
Hillary Frommer		Present
Zainab Shahid		Absent
Geoffrey Ku		Absent
Rui Gardner		Present
Marc Kramer		Present
Sham Mailankody		Present
Paul O'Brien		Present
Andrea Ventura		Present
Christine Iacobuzio-Donahue		Present
Shuchi Agarwal		Present

NON-VOTING ATTENDEES/GUESTS

Asmita Kumar
Rivka Schwarcz
Timothy Burnett
Gary Martin

QUORUM INFORMATION**Number of SAFETY members on the roster:** 18**Number required for quorum:** 10

All members present by teleconference received all pertinent material before the meeting and were able to actively and equally participate in all discussions.

ATTENDANCE STATUS AND VOTING KEYMinutes Prepared: [January 29, 2026](#)[January 26, 2026](#)Template Revision: [January 29, 2026](#)[January 23, 2026](#)

ABSTAIN:	Present for the vote but not voting “For” or “Against.”
ABSENT:	Absent for discussion and voting for reasons other than a conflicting interest.
RECUSED:	Absent from the meeting during discussion and voting because of a conflicting interest.
SUBSTITUTION:	When regular members and their alternate(s) are listed in the ATTENDANCE table above and an alternate member substitute for the regular member this identifies the name of the alternate to indicate which individual is serving as the voting member for this vote. May be deleted if there are no substitutions.

DISCUSSION

The Minutes from the October 2025 Meeting were approved.

The NIH Office of Science Policy now requires institutions to provide the URL where they publicly post their IBC Minutes. This follows a previous requirement to make IBC Minutes publicly available for all meetings occurring on or after June 1, 2025.

REVIEW OF CLINICAL SUBMISSIONS

Initial Protocol

1. Review of PROTO202500019

Title:	MED25-225: A Single-Arm, Open-Label, Multi-Center, Phase 1b/ 2 Study to Evaluate the Safety, Efficacy, and Cellular Pharmacokinetic Profile of CTD402 in Participants with Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic L
Investigator:	Mark Geyer
Submission ID	PROTO202500019

- a. **Determination:** Approved
- b. **Last day of continuing review period:** 12/31/2026
- c. **Required modifications:** None
- d. **Comments:** This is a phase 1b/2, single-arm, open-label, multi-center study evaluating the safety, efficacy, and cellular pharmacokinetics of CTD402 in patients with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). The primary objective of phase 1b is to characterize the safety profile of CTD402, while the primary objective of phase 2 is to determine its efficacy in this patient population. The Reviewer did not express any concerns and recommended approval. The Committee voted to approve the trial.
- e. **Applicable section of NIH Guidelines:** Section III-C-1
- f. **Containment level:** BSL-2
- g. **Votes:**

For:	11
Against:	0

Recused: 1
Absent: 6
Abstained: 0

Amendment/CR**2. Review of SAF03900**

Title:	Amendment/CR for PROTO202400024
Investigator:	Alexander Boardman
Submission ID	SAF03900

- a. **Determination:** Approved
- b. **Last day of continuing review period:** 12/31/2026
- c. **Required modifications:** None
- d. **Comments:** This is the amendment and annual review for a phase 2 study of a combination of Lisocabtagene Maraleucel, Nivolumab, and Ibrutinib in Richter's transformation (RT). The goal of treatment is to achieve a complete remission (CR) and proceed to consolidative allogeneic hematopoietic cell transplantation (alloHCT). No accidents, exposures or loss of containment were reported. The purpose of the amendment is to update personnel and administrative documents. The Reviewer did not have any concerns and recommended approval. The Committee voted to approve the amendment and annual review.
- e. **Applicable section of NIH Guidelines:** Section III-C-1
- f. **Containment level:** BSL-2
- g. **Votes:**
 - For:** 11
 - Against:** 0
 - Recused:** 1
 - Absent:** 6
 - Abstained:** 0

Amendment/CR**3. Review of SAF03921**

Title:	Amendment/CR for PROTO201600001
Investigator:	Shanu Modi
Submission ID	SAF03921

- a. **Determination:** Approved
- b. **Last day of continuing review period:** 12/31/2026
- c. **Required modifications:** None
- d. **Comments:** This is the amendment and annual review for a phase I Clinical Trial to Evaluate the Safety and Tolerability of Mesothelin-specific Chimeric Antigen Receptor (CAR)-positive T-Cells in Patients with Metastatic Mesothelin-expressing Breast Cancer. The primary objective of this trial is to assess the safety and dose requirement of intravenously administered genetically directed autologous human T

cells targeted to mesothelin, a cell surface cancer antigen widely expressed in HER2-negative breast cancer, using a chimeric antigen receptor (CAR). No accidents, exposures or loss of containment were reported. The purpose of the amendment is to update personnel and administrative documents. The Reviewer did not have any concerns and recommended approval. The Committee voted to approve the amendment and annual review.

- e. **Applicable section of NIH Guidelines:** Section III-C-1
- f. **Containment level:** BSL-2
- g. **Votes:**
 - For:** 12
 - Against:** 0
 - Recused:** 0
 - Absent:** 6
 - Abstained:** 0

Amendment/CR

4. Review of SAF03912

Title:	Amendment/CR for PROTO202300031
Investigator:	Sham Mailankody
Submission ID	SAF03912

- a. **Determination:** Approved
- b. **Last day of continuing review period:** 12/31/2026
- c. **Required modifications:** None
- d. **Comments:** This is the amendment and annual review for a Phase 1, multicenter, open-label study to determine the optimal target dose, safety, and efficacy of BMS-986453, a dual targeting CAR T-cell product targeting BCMA and GPRC5D, in participants with relapsed/refractory multiple myeloma (RRMM). The primary objectives are to evaluate the safety and tolerability of BMS-986453 in participants with RRMM and to determine the MTD and/or RP2D of BMS-986453. No accidents, exposures or loss of containment were reported. The purpose of the amendment is to update personnel and administrative documents. The Reviewer did not have any concerns and recommended approval. The Committee voted to approve the amendment and annual review.
- e. **Applicable section of NIH Guidelines:** Section III-C-1
- f. **Containment level:** BSL-2
- g. **Votes:**
 - For:** 11
 - Against:** 0
 - Recused:** 1
 - Absent:** 6
 - Abstained:** 0

Amendment/CR

5. Review of SAF03906

Title:	Amendment/CR for PROTO202000026
Investigator:	Sridevi Rajeeve
Submission ID	SAF03906

- a. **Determination:** Approved
- b. **Last day of continuing review period:** 12/31/2026
- c. **Required modifications:** None
- d. **Comments:** This is the amendment and annual review for a Phase 2, Open-Label, multicenter study of JNJ-68284528 administered to adult subjects with relapsed or refractory multiple myeloma. The primary objective of the study is to evaluate the overall minimal residual disease (MRD) negative rate of subjects who receive JNJ-68284528. No accidents, exposures or loss of containment were reported. The purpose of the amendment is to update administrative documents. The Reviewer did not have any concerns and recommended approval. The Committee voted to approve the amendment and annual review.
- e. **Applicable section of NIH Guidelines:** Section III-C-1
- f. **Containment level:** BSL-2
- g. **Votes:**

For:	10
Against:	0
Recused:	2
Absent:	6
Abstained:	0

Amendment/CR

6. Review of SAF03891

Title:	Amendment/CR for PROTO202100017
Investigator:	Gunjan Shah
Submission ID	SAF03891

- a. **Determination:** Approved
- b. **Last day of continuing review period:** 12/31/2026
- c. **Required modifications:** None
- d. **Comments:** This is the amendment and annual review for a Feasibility Trial of Autologous Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy Using Ide-Cel for Multiple Myeloma Patients Status Post Hematopoietic Cell Transplantation. The primary objective of this research study is to estimate the feasibility of manufacturing Ide-Cel (to dose of at least 300 million cells) in patients. No accidents, exposures or loss of containment were reported. The purpose of the amendment is to update personnel and administrative documents. The Reviewer did not have any concerns and recommended approval. The Committee voted to approve the amendment and annual review.
- e. **Applicable section of NIH Guidelines:** Section III-C-1
- f. **Containment level:** BSL-2

g. **Votes:**

For: 11
Against: 0
Recused: 1
Absent: 6
Abstained: 0

Amendment**7. Review of SAF03878**

Title:	Amendment for PROTO202200007
Investigator:	Lara Dunn
Submission ID	SAF03878

- a. **Determination:** Approved
- b. **Last day of continuing review period:** 12/31/2026
- c. **Required modifications:** None
- d. **Comments:** This amendment is for making editorial updates in the protocol to correctly reflect the approved containment level. The Reviewer pointed out several locations within the protocol where the containment levels were inconsistent. This was corrected and the Reviewer did not have any concerns and recommended approval. The Committee voted to approve the amendment.
- e. **Applicable section of NIH Guidelines:** Section III-C-1
- f. **Containment level:** BSL-2
- g. **Votes:**
- For:** 12
Against: 0
Recused: 0
Absent: 6
Abstained: 0

REVIEW OF LABORATORY SUBMISSIONS**Triennial Protocol****8. Review of LAB202500113**

Title:	Antibody and Bioresource Core Facility (Frances Weis-Garcia)
Investigator:	Frances Weis-Garcia
Submission ID	LAB202500113

- a. **Determination:** Approved
- b. **Last day of continuing review period:** 12/31/2026
- c. **Required modifications:** None
- d. **Comments:** This is the triennial review for the Antibody and Bioresource Core Facility, which develops new monoclonal antibodies and distributes published cell lines developed at MSK or Rockefeller University around the world. The Reviewer

did not have any concerns and recommended approval. The Committee voted to approve the triennial review.

- e. **Applicable section of NIH Guidelines:** III-F-8, Appendix C-I
- f. **Containment level:** BSL-2
- g. **Votes:**

For: 12
Against: 0
Recused: 0
Absent: 6
Abstained: 0

Triennial Protocol

9. Review of LAB202500109

Title:	Morgan Huse lab
Investigator:	Morgan Huse
Submission ID	LAB202500109

- a. **Determination:** Approved
- b. **Last day of continuing review period:** 12/31/2026
- c. **Required modifications:** None
- d. **Comments:** This is the triennial review for the Huse lab which uses single cell imaging approaches to understand the structure and function of immune cell-cell interactions and study immunotherapeutic anti-tumor responses. The Reviewer did not have any concerns and recommended approval. The Committee voted to approve the triennial review.
- e. **Applicable section of NIH Guidelines:** III-F-8, Appendix C-I, III-F-8, Appendix C-II, III-D-1-a, III-D-3-b, III-E
- f. **Containment level:** BSL-2
- g. **Votes:**

For: 12
Against: 0
Recused: 0
Absent: 6
Abstained: 0

Triennial Protocol

10. Review of LAB202500108

Title:	John Chodera Lab
Investigator:	John Chodera
Submission ID	LAB202500108

- a. **Determination:** Approved
- b. **Last day of continuing review period:** 12/31/2026
- c. **Required modifications:** None

- d. **Comments:** This is the triennial review for the Chodera lab which combines computational modeling and automated biophysical experiments to improve computational models for designing new small molecule therapeutics. The Reviewer did not have any concerns and recommended approval. The Committee voted to approve the triennial review.
- e. **Applicable section of NIH Guidelines:** III-F-8 Appendix C-II
- f. **Containment level:** BSL-1
- g. **Votes:**
 - For:** 12
 - Against:** 0
 - Recused:** 0
 - Absent:** 6
 - Abstained:** 0

Triennial Protocol**11. Review of LAB202500110**

Title:	Karuna Ganesh Lab
Investigator:	Karuna Ganesh
Submission ID	LAB202500110

- a. **Determination:** Approved
- b. **Last day of continuing review period:** 12/31/2026
- c. **Required modifications:** None
- d. **Comments:** This is the triennial review for the Ganesh lab which studies the mechanisms underlying the persistence, therapy resistance and immune evasion of metastasis stem cells. The Reviewer did not have any concerns and recommended approval. The Committee voted to approve the triennial review.
- e. **Applicable section of NIH Guidelines:** III-F-8, Appendix C-I, III-F-8 Appendix C-II, III-D-3-a, III-D-3-b
- f. **Containment level:** BSL-2
- g. **Votes:**
 - For:** 12
 - Against:** 0
 - Recused:** 0
 - Absent:** 6
 - Abstained:** 0

Triennial Protocol**12. Review of LAB202500115**

Title:	Mara Sherman Lab
Investigator:	Mara Sherman
Submission ID	LAB202500115

- a. **Determination:** Approved

- b. **Last day of continuing review period:** 12/31/2026
- c. **Required modifications:** None
- d. **Comments:** This is the triennial review for the Sherman lab which studies cell-cell interactions in the pancreatic tumor microenvironment and their significance for disease progression. The Reviewer did not have any concerns and recommended approval. The Committee voted to approve the triennial review.
- e. **Applicable section of NIH Guidelines:** III-F-8, Appendix C-I, III-F-8 Appendix C-II, III-D-3-b, III-D-1-a
- f. **Containment level:** BSL-2
- g. **Votes:**
 - For:** 12
 - Against:** 0
 - Recused:** 0
 - Absent:** 6
 - Abstained:** 0

Triennial Protocol

13. Review of LAB202500111

Title:	Michael Kharas Lab
Investigator:	Michael Kharas
Submission ID	LAB202500111

- a. **Determination:** Approved
- b. **Last day of continuing review period:** 12/31/2026
- c. **Required modifications:** None
- d. **Comments:** This is the triennial review for the Kharas lab which aims to identify critical pathways in both normal and leukemic hematopoietic stem cells (HSC). The Reviewer did not have any concerns and recommended approval. The Committee voted to approve the triennial review.
- e. **Applicable section of NIH Guidelines:** III-F-8, Appendix C-I, III-F-8 Appendix C-II, III-D-3-a, III-D-3-b
- f. **Containment level:** BSL-2
- g. **Votes:**
 - For:** 12
 - Against:** 0
 - Recused:** 0
 - Absent:** 6
 - Abstained:** 0

Initial Protocol

14. Review of LAB202500116

Title:	Cell Metabolism Core Laboratory (Mara Monetti)
Investigator:	Mara Monetti
Submission ID	LAB202500116

- a. **Determination:** Approved
- b. **Last day of continuing review period:** 12/31/2026
- c. **Required modifications:** None
- d. **Comments:** This is the Initial review for the Cell Metabolism Core Laboratory, which helps investigators characterize biological systems through the direct measurement of the small molecule constituents. The Reviewer did not have any concerns and recommended approval. The Committee voted to approve the triennial review.
- e. **Applicable section of NIH Guidelines:** III-F-8, Appendix C-I
- f. **Containment level:** BSL-2
- g. **Votes:**

For:	12
Against:	0
Recused:	0
Absent:	6
Abstained:	0

Triennial Protocol

15. Review of LAB202500114

Title:	Jan Grimm Lab
Investigator:	Jan Grimm
Submission ID	LAB202500114

- a. **Determination:** Approved
- b. **Last day of continuing review period:** 12/31/2026
- c. **Required modifications:** None
- d. **Comments:** This is the triennial review for the Grimm lab which characterizes the role of prostate specific membrane antigen in prostate cancer and neovasculature. The Reviewer did not have any concerns and recommended approval. The Committee voted to approve the triennial review.
- e. **Applicable section of NIH Guidelines:** III-F-8, Appendix C-I, III-F-8 Appendix C-II, III-D-3-a, III-E
- f. **Containment level:** BSL-2
- g. **Votes:**

For:	12
Against:	0
Recused:	0
Absent:	6
Abstained:	0

Commented [AK1]: Please explain to me what happened with this submission. Why was it administratively approved?

Continuing Review**16. Review of SAF03911**

Title:	Continuing Review for LAB202400018
Investigator:	Hooman Yarmohammadi
Submission ID	SAF03911

- a. **Determination:** Approved
- b. **Last day of continuing review period:** 12/31/2026
- c. **Required modifications:** None
- d. **Comments:** This annual review is for the Yarmohammadi Lab which aims to improve the success rate of tumor embolization and ablation. No changes, accidents, exposures, or loss of containment were reported. The Committee voted to approve the annual review.
- e. **Applicable section of NIH Guidelines:** III-F-8, Appendix C-I, III-D-1-a
- f. **Containment level:** BSL-2
- g. **Votes:**
 - For:** 12
 - Against:** 0
 - Recused:** 0
 - Absent:** 6
 - Abstained:** 0

Continuing Review**17. Review of SAF03908**

Title:	Continuing Review for LAB202300070
Investigator:	Carl Lekaye
Submission ID	SAF03908
Funding:	None
Documents Reviewed:	None

- a. **Determination:** Approved
- b. **Last day of continuing review period:** 12/31/2026
- c. **Required modifications:** None
- d. **Comments:** This annual review is for the Lekaye Lab which studies the effects of inhibiting IDH1 mutation on tumor radiosensitivity. No changes, accidents, exposures, or loss of containment were reported. The Committee voted to approve the annual review.
- e. **Applicable section of NIH Guidelines:** III-F-8, Appendix C-I
- f. **Containment level:** BSL-2
- g. **Votes:**
 - For:** 12
 - Against:** 0
 - Recused:** 0
 - Absent:** 6
 - Abstained:** 0

Continuing Review**18. Review of SAF03907**

Title:	Continuing Review for LAB202300031
Investigator:	Scott Lowe
Submission ID	SAF03907

- a. **Determination:** Approved
- b. **Last day of continuing review period:** 12/31/2026
- c. **Required modifications:** None
- d. **Comments:** This annual review is for the Lowe Lab which studies the genetic alterations in cancer cells that contribute to tumorigenesis, alter treatment response, and create vulnerabilities that may be targeted therapeutically. No changes or loss of containment were reported. A needlestick accident was reported to the Biosafety Officer and EHS. The lab member completed training refreshers. Employee Health was consulted for post-exposure evaluation. The Reviewer did not have any concerns and recommended approval. The Committee voted to approve the annual review.
- e. **Applicable section of NIH Guidelines:** III-F-8, Appendix C-I, III-F-8 Appendix C-II, III-D-1-a, III-D-3-b
- f. **Containment level:** BSL-2
- g. **Votes:**
 - For:** 12
 - Against:** 0
 - Recused:** 0
 - Absent:** 6
 - Abstained:** 0

Continuing Review**19. Review of SAF03919**

Title:	Continuing Review for LAB202300062
Investigator:	Santosha Vardhana
Submission ID	SAF03919

- a. **Determination:** Approved
- b. **Last day of continuing review period:** 12/31/2026
- c. **Required modifications:** None
- d. **Comments:** This annual review is for the Vardhana Lab which studies how alterations in nutrient availability and cellular metabolism affect immune responses during both infections and cancer. No changes, accidents, exposures, or loss of containment were reported. The Committee voted to approve the annual review.
- e. **Applicable section of NIH Guidelines:** III-F-8, Appendix C-I, III-D-3-b, III-F-8 Appendix C-II, III-D-1-a
- f. **Containment level:** BSL-2
- g. **Votes:**

For: 12
Against: 0
Recused: 0
Absent: 6
Abstained: 0

Continuing review with amendment**20. Review of SAMENDCR202500000036**

Title:	Amendment/CR for LAB202300042
Investigator:	Manu Jain
Submission ID	SAMENDCR202500000036

- a. **Determination:** Approved
- b. **Last day of continuing review period:** 12/31/2026
- c. **Required modifications:** None
- d. **Comments:** This is the amendment and the annual review for the Jain Lab. This lab tests samples obtained from animals or humans for histopathology evaluation and compares these results with the outcomes of new diagnostic techniques. No accidents, exposures or loss of containment have occurred. The purpose of the amendment is to update personnel. The Committee voted to approve the amendment and annual review.
- e. **Applicable section of NIH Guidelines:** III-F-8
- f. **Containment level:** BSL-2+
- g. **Votes:**

For: 12
Against: 0
Recused: 0
Absent: 6
Abstained: 0

Continuing review with amendment**21. Review of SAMENDCR202500000035**

Title:	Amendment/CR for LAB202300072
Investigator:	Dinshaw Patel
Submission ID	SAMENDCR202500000035

- a. **Determination:** Approved
- b. **Last day of continuing review period:** 12/31/2026
- c. **Required modifications:** None
- d. **Comments:** This is the amendment and the annual review for the Patel Lab. The lab uses crystallographic, solution NMR and cryo EM techniques to investigate macromolecular-mediated recognition, regulation, and catalysis. No accidents, exposures or loss of containment have occurred. The purpose of the amendment is to

update personnel. The Committee voted to approve the amendment and annual review.

- e. **Applicable section of NIH Guidelines:** III-F-8 Appendix C-I, III-F-8 Appendix C-II, III-E
- f. **Containment level:** BSL-2
- g. **Votes:**
 - For:** 12
 - Against:** 0
 - Recused:** 0
 - Absent:** 6
 - Abstained:** 0

Continuing review with amendment

22. Review of SAF03890

Title:	Amendment/CR for LAB202300075
Investigator:	Piro Lito
Submission ID	SAF03890

- a. **Determination:** Approved
- b. **Last day of continuing review period:** 12/31/2026
- c. **Required modifications:** None
- d. **Comments:** This is the amendment and the annual review for the Lito Lab. The lab studies the properties of oncoproteins that drive cancer cell growth, focusing on lung cancer and other solid tumors. No accidents, exposures or loss of containment have occurred. The purpose of the amendment is to update personnel. The Committee voted to approve the amendment and annual review.
- e. **Applicable section of NIH Guidelines:** III-F-8, Appendix C-I, III-D-3-b, III-F-8 Appendix C-II
- f. **Containment level:** BSL-2
- g. **Votes:**
 - For:** 12
 - Against:** 0
 - Recused:** 0
 - Absent:** 6
 - Abstained:** 0

Continuing review with amendment

23. Review of SAF03889

Title:	Amendment/CR for LAB202300074
Investigator:	Mara Monetti
Submission ID	SAF03889

- a. **Determination:** Approved
- b. **Last day of continuing review period:** 12/31/2026

- c. **Required modifications:** None
- d. **Comments:** This is the amendment and the annual review for the Proteomics Core. This core performs mass spectrometry-based analyses of proteins and peptides for the purpose of identification, relative quantitative analysis, and post-translational modification (PTM) analysis. No accidents, exposures or loss of containment have occurred. The purpose of the amendment is to update personnel and add PDX samples. The Committee voted to approve the amendment and annual review.
- e. **Applicable section of NIH Guidelines:** III-F-8, Appendix C-I
- f. **Containment level:** BSL-2
- g. **Votes:**
 - For:** 12
 - Against:** 0
 - Recused:** 0
 - Absent:** 6
 - Abstained:** 0

Amendment**24. Review of SAMEND202500000007**

Title:	Amendment for LAB202500059
Investigator:	Adam Schmitt
Submission ID	SAMEND202500000007

- a. **Determination:** Approved
- b. **Last day of continuing review period:** 8/31/2026
- c. **Required modifications:** None
- d. **Comments:** This amendment is for making editorial corrections. The Reviewer did not have any concerns and recommended approval. The Committee voted to approve the amendment.
- e. **Applicable section of NIH Guidelines:** N/A
- f. **Containment level:** BSL-2
- g. **Votes:**
 - For:** 12
 - Against:** 0
 - Recused:** 0
 - Absent:** 6
 - Abstained:** 0

Amendment**25. Review of SAF03910**

Title:	Amendment for LAB202500077
Investigator:	Kayvan Rahimi-Keshari
Submission ID	SAF03910

- a. **Determination:** Approved

- b. **Last day of continuing review period:** 9/30/2026
- c. **Required modifications:** None
- d. **Comments:** This amendment is for adding primary human cells. The Reviewer did not have any concerns and recommended approval. The Committee voted to approve the amendment.
- e. **Applicable section of NIH Guidelines:** III-F-8, Appendix C-I
- f. **Containment level:** BSL-2
- g. **Votes:**
 - For:** 12
 - Against:** 0
 - Recused:** 0
 - Absent:** 6
 - Abstained:** 0

Amendment**26. Review of SAF03920**

Title:	Amendment for LAB202500088
Investigator:	Kojo Elenitoba-Johnson
Submission ID	SAF03920

- a. **Determination:** Approved
- b. **Last day of continuing review period:** 9/30/2026
- c. **Required modifications:** None
- d. **Comments:** This amendment is for adding 3rd generation Lenti-CRISPR/Cas9. The Reviewer did not have any concerns and recommended approval. The Committee voted to approve the amendment.
- e. **Applicable section of NIH Guidelines:** III-D-3-b
- f. **Containment level:** BSL-2
- g. **Votes:**
 - For:** 12
 - Against:** 0
 - Recused:** 0
 - Absent:** 6
 - Abstained:** 0

Amendment**27. Review of SAF03909**

Title:	Amendment for LAB202300068
Investigator:	Caleb Lareau
Submission ID	SAF03909

- a. **Determination:** Approved
- b. **Last day of continuing review period:** 5/26/2026
- c. **Required modifications:** None

- d. **Comments:** This amendment is for adding engineered T cell therapies from human T cells. The Reviewer did not have any concerns and recommended approval. The Committee voted to approve the amendment.
- e. **Applicable section of NIH Guidelines:** III-F-8, Appendix C-I
- f. **Containment level:** BSL-2+
- g. **Votes:**
 - For:** 12
 - Against:** 0
 - Recused:** 0
 - Absent:** 6
 - Abstained:** 0